Exploring all structural space in the universe to deliver new therapies for diseases where no treatment has ever existed. The convergence of AI, theoretical science, and computational drug discovery makes the impossible achievable.
Bringing new hope to diseases with no existing therapy. Through a theory-driven approach that requires no dependency on known data, Myracule generates unprecedented compounds — opening doors that conventional drug discovery cannot.
Myracule's platform explores structures at a scale of 10²⁰ — a comprehensiveness that dwarfs every existing database combined. This is not curation of the known; it is systematic creation of the possible.
Total structural space explored — beyond any existing database on Earth.
A fully theory-driven engine with no dependency on historical molecular datasets.
Every compound generated is structurally unprecedented — no recycled scaffolds.
Applicable across all disease areas where structural information is available. A theory-driven engine that requires no training data cuts through the limitations of AI models bound by historical bias — opening uncharted chemical space for the first time.
Systematically enumerates all compounds without relying on known chemical databases or curated datasets.
High-precision molecular matching grounded in quantum chemistry — beyond fingerprint-based approximations.
Binding site scoring identifies optimal interaction points on target proteins, guiding compound selection with maximal accuracy.
No training data required — enabling exploration of untreated diseases where historical molecular data simply does not exist.
From target protein to lead compound candidate — a seamless, automated pipeline that operates at unprecedented scale and precision. Each stage is fully automated and operates without dependency on existing compound libraries — enabling discovery in disease areas previously considered intractable.
This end-to-end pipeline requires no human intervention or curated compound input — making Myracule uniquely suited for disease indications that have never before been addressed computationally.
For organizations exploring access to uncharted compound structural space — whether in partnership, licensing, or co-development — Myracule is ready to engage. Let's discuss how theory-driven discovery can accelerate your pipeline.
Explore co-development opportunities targeting your priority disease indications.
License Myracule's computational discovery engine for integration into your existing R&D workflow.
Connect with our team to explore how the platform applies to your specific target biology.
Reach us at info@myracule.com
Myriads of Molecules Bring Miracle